The effect of hyperlipidemic state on urine expression of rifampicin and its association with pulmonary tuberculosis-a prospective pilot study

Sumanth Madan, K. Meena Kumari, Afreen A. Choudhry, Suhasini Kamath, Asha Kamath, Mohan Babu Amberkar, Pragna Rao, Rahul Magazine, Rudra Ramanathan

Research output: Contribution to journalArticle

Abstract

Objectives: Rifampicin is an antibiotic that imparts an orange-red colour to the urine for a few hours after a dose. About 7% of the administered drug is excreted through the urine. This study compared the urine colour expression of rifampicin in normal and hyperlipidaemic subjects. Methods: A cohort pilot study was conducted at a tertiary care hospital in which eight subjects with tuberculosis with normal lipid profiles and twelve subjects with deranged lipid profiles were given one tablet of rifampicin (450 mg) in the morning on empty stomach over one month. After one month urine samples was collected at 1,3 and 5 hours. The quantity of rifampicin in urine was estimated using a spectrophotometer. The results were analysed using SPSS version 18. Results: Twenty patients with pulmonary tuberculosis and on rifampicin 450mg were taken for this study. Their urine was analysed for concentration of rifampicin and correlated to their total cholesterol and triglycerides values. The median total cholesterol in the study group was 345.5 mg/dL whereas in control group was 145.5 mg/dL. The median triglycerides in study group was 436 mg/dL in comparison to control group 113.5 mg/dl. The mean urine concentration of rifampicin in study group at 1hr,3h and 5 h was (47.08 ±17.17),(102.5±134.57) and (63.75±38.027)mcg/dl respectively in comparison to control group (53.13±14.126),(199.38±146.2) and (215.63±164.825) mcg/dL respectively at 1,3 and 5 h. Conclusion: The study shows that hyperlipidemia may be associated with decreased level of rifampicin, leading to therapeutic failure in tuberculosis patients.

Original languageEnglish
Pages (from-to)99-102
Number of pages4
JournalInternational Journal of Pharmacy and Pharmaceutical Sciences
Volume6
Issue number7
Publication statusPublished - 01-01-2014

Fingerprint

Rifampin
Pulmonary Tuberculosis
Urine
Prospective Studies
Control Groups
Triglycerides
Tuberculosis
Color
Cholesterol
Lipids
Tertiary Healthcare
Hyperlipidemias
Tertiary Care Centers
Tablets
Stomach
Cohort Studies
Anti-Bacterial Agents
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{5ca8bc4851464a0dbdca6fb693df225f,
title = "The effect of hyperlipidemic state on urine expression of rifampicin and its association with pulmonary tuberculosis-a prospective pilot study",
abstract = "Objectives: Rifampicin is an antibiotic that imparts an orange-red colour to the urine for a few hours after a dose. About 7{\%} of the administered drug is excreted through the urine. This study compared the urine colour expression of rifampicin in normal and hyperlipidaemic subjects. Methods: A cohort pilot study was conducted at a tertiary care hospital in which eight subjects with tuberculosis with normal lipid profiles and twelve subjects with deranged lipid profiles were given one tablet of rifampicin (450 mg) in the morning on empty stomach over one month. After one month urine samples was collected at 1,3 and 5 hours. The quantity of rifampicin in urine was estimated using a spectrophotometer. The results were analysed using SPSS version 18. Results: Twenty patients with pulmonary tuberculosis and on rifampicin 450mg were taken for this study. Their urine was analysed for concentration of rifampicin and correlated to their total cholesterol and triglycerides values. The median total cholesterol in the study group was 345.5 mg/dL whereas in control group was 145.5 mg/dL. The median triglycerides in study group was 436 mg/dL in comparison to control group 113.5 mg/dl. The mean urine concentration of rifampicin in study group at 1hr,3h and 5 h was (47.08 ±17.17),(102.5±134.57) and (63.75±38.027)mcg/dl respectively in comparison to control group (53.13±14.126),(199.38±146.2) and (215.63±164.825) mcg/dL respectively at 1,3 and 5 h. Conclusion: The study shows that hyperlipidemia may be associated with decreased level of rifampicin, leading to therapeutic failure in tuberculosis patients.",
author = "Sumanth Madan and {Meena Kumari}, K. and Choudhry, {Afreen A.} and Suhasini Kamath and Asha Kamath and Amberkar, {Mohan Babu} and Pragna Rao and Rahul Magazine and Rudra Ramanathan",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "99--102",
journal = "International Journal of Pharmacy and Pharmaceutical Sciences",
issn = "0975-1491",
publisher = "IJPPS",
number = "7",

}

TY - JOUR

T1 - The effect of hyperlipidemic state on urine expression of rifampicin and its association with pulmonary tuberculosis-a prospective pilot study

AU - Madan, Sumanth

AU - Meena Kumari, K.

AU - Choudhry, Afreen A.

AU - Kamath, Suhasini

AU - Kamath, Asha

AU - Amberkar, Mohan Babu

AU - Rao, Pragna

AU - Magazine, Rahul

AU - Ramanathan, Rudra

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: Rifampicin is an antibiotic that imparts an orange-red colour to the urine for a few hours after a dose. About 7% of the administered drug is excreted through the urine. This study compared the urine colour expression of rifampicin in normal and hyperlipidaemic subjects. Methods: A cohort pilot study was conducted at a tertiary care hospital in which eight subjects with tuberculosis with normal lipid profiles and twelve subjects with deranged lipid profiles were given one tablet of rifampicin (450 mg) in the morning on empty stomach over one month. After one month urine samples was collected at 1,3 and 5 hours. The quantity of rifampicin in urine was estimated using a spectrophotometer. The results were analysed using SPSS version 18. Results: Twenty patients with pulmonary tuberculosis and on rifampicin 450mg were taken for this study. Their urine was analysed for concentration of rifampicin and correlated to their total cholesterol and triglycerides values. The median total cholesterol in the study group was 345.5 mg/dL whereas in control group was 145.5 mg/dL. The median triglycerides in study group was 436 mg/dL in comparison to control group 113.5 mg/dl. The mean urine concentration of rifampicin in study group at 1hr,3h and 5 h was (47.08 ±17.17),(102.5±134.57) and (63.75±38.027)mcg/dl respectively in comparison to control group (53.13±14.126),(199.38±146.2) and (215.63±164.825) mcg/dL respectively at 1,3 and 5 h. Conclusion: The study shows that hyperlipidemia may be associated with decreased level of rifampicin, leading to therapeutic failure in tuberculosis patients.

AB - Objectives: Rifampicin is an antibiotic that imparts an orange-red colour to the urine for a few hours after a dose. About 7% of the administered drug is excreted through the urine. This study compared the urine colour expression of rifampicin in normal and hyperlipidaemic subjects. Methods: A cohort pilot study was conducted at a tertiary care hospital in which eight subjects with tuberculosis with normal lipid profiles and twelve subjects with deranged lipid profiles were given one tablet of rifampicin (450 mg) in the morning on empty stomach over one month. After one month urine samples was collected at 1,3 and 5 hours. The quantity of rifampicin in urine was estimated using a spectrophotometer. The results were analysed using SPSS version 18. Results: Twenty patients with pulmonary tuberculosis and on rifampicin 450mg were taken for this study. Their urine was analysed for concentration of rifampicin and correlated to their total cholesterol and triglycerides values. The median total cholesterol in the study group was 345.5 mg/dL whereas in control group was 145.5 mg/dL. The median triglycerides in study group was 436 mg/dL in comparison to control group 113.5 mg/dl. The mean urine concentration of rifampicin in study group at 1hr,3h and 5 h was (47.08 ±17.17),(102.5±134.57) and (63.75±38.027)mcg/dl respectively in comparison to control group (53.13±14.126),(199.38±146.2) and (215.63±164.825) mcg/dL respectively at 1,3 and 5 h. Conclusion: The study shows that hyperlipidemia may be associated with decreased level of rifampicin, leading to therapeutic failure in tuberculosis patients.

UR - http://www.scopus.com/inward/record.url?scp=84905506587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905506587&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 99

EP - 102

JO - International Journal of Pharmacy and Pharmaceutical Sciences

JF - International Journal of Pharmacy and Pharmaceutical Sciences

SN - 0975-1491

IS - 7

ER -